Tight Risk Reward, Good Company

NASDAQ:MRSN   Mersana Therapeutics, Inc
Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate ( ADC ) for cancer patients with unmet need.

  • After an insider at Mersana Therapeutics bought shares following a May 2020 selloff triggered by an interim data release, the stock rallied over 400% during the next eight months.
    Another bounce back may emerge again with an insider purchasing shares after a one-day plunge of nearly 30% on tepid but still encouraging data from its lead ADC asset.
    A 180-patient single-arm registrational trial is set to be initiated for XMT-1536 in the treatment of platinum-resistant ovarian cancer this quarter.
    With early-stage clinical data due from both its candidates in the treatment of NSCLC adenocarcinoma in 2H21, Mersana merited another look.

I like it long here as tight risk-reward play.


Im gonna buy this
Super !